Endothelin receptor antagonist

• Endothelin receptor antagonists (ERAs) are a class of medications that target the endothelin system, a crucial regulatory pathway involved in the control of vascular tone and fluid balance.
• ERAs act by blocking the binding of endothelin to its receptors, thereby inhibiting its vasoconstrictive and proliferative effects.

Sparsentan

Mechanism of Action

• Endothelin is a potent peptide hormone that exists in three isoforms: endothelin-1 (ET-1), endothelin-2 (ET-2), and endothelin-3 (ET-3).
• It is produced by endothelial cells, smooth muscle cells, and other tissues and acts on two main receptor subtypes: endothelin A receptor (ETA) and endothelin B receptor (ETB).
• When endothelin binds to ETA receptors on vascular smooth muscle cells, it causes vasoconstriction and promotes cell proliferation, leading to an increase in blood pressure and potential vascular remodeling.
• On the other hand, activation of ETB receptors can lead to both vasoconstriction and vasodilation, depending on the location and type of receptor (endothelial or smooth muscle).
• ETB receptors on endothelial cells play a vasodilatory role by promoting the release of nitric oxide and prostacyclin, counteracting the vasoconstrictive effects.

• Endothelin receptor antagonists selectively block the ETA and ETB receptors, thus inhibiting the actions of endothelin.
• By doing so, they cause vasodilation, reduce vascular resistance, and decrease blood pressure, making them valuable therapeutic agents in certain cardiovascular and pulmonary conditions.

Medical Uses

• Endothelin receptor antagonists have demonstrated clinical efficacy in the management of various medical conditions:

1. Pulmonary Arterial Hypertension (PAH)

• PAH is a severe and progressive condition characterized by elevated blood pressure in the pulmonary arteries, leading to right heart strain and heart failure.
• ERAs are an essential component of PAH therapy and have been shown to improve exercise capacity, hemodynamics, and overall quality of life in affected patients.

2. Digital Ulcers in Systemic Sclerosis

• ERAs are used to treat digital ulcers, a common complication of systemic sclerosis (scleroderma). By improving peripheral blood flow and reducing vasoconstriction, they can help promote healing and prevent complications.

3. Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

• CTEPH is a form of pulmonary hypertension caused by chronic thromboembolic obstructions in the pulmonary arteries. ERAs can be considered as a treatment option for patients with inoperable or persistent CTEPH.

Side Effects

While endothelin receptor antagonists are generally well-tolerated, they may be associated with certain side effects:

• Liver Toxicity: Some ERAs have been linked to hepatotoxicity, necessitating regular monitoring of liver function during treatment.
• Fluid Retention: In some cases, fluid retention and peripheral edema may occur, especially in patients with heart failure.
• Anemia: ERAs may cause a decrease in hemoglobin levels, leading to anemia.
• Headache and Dizziness: Central nervous system effects, such as headache and dizziness, have been reported in some patients.
• It is crucial for healthcare providers to monitor patients receiving ERAs for any adverse effects and adjust treatment as needed.

Notable Examples of Endothelin Receptor Antagonists

There are several endothelin receptor antagonists approved for medical use, including:

• Bosentan: A non-selective ERA that blocks both ETA and ETB receptors, approved for PAH and digital ulcers in systemic sclerosis.
• Ambrisentan: A selective ETA receptor antagonist indicated for PAH.
• Macitentan: A dual ETA and ETB receptor antagonist used for PAH treatment.
• Sitaxentan (no longer marketed): A selective ETA receptor antagonist previously used for PAH but withdrawn due to potential liver toxicity.

Conclusion

• Endothelin receptor antagonists are valuable therapeutic agents in the management of certain cardiovascular and pulmonary conditions.
• By selectively blocking endothelin receptors, they help promote vasodilation, reduce vascular resistance, and improve clinical outcomes in patients with conditions like PAH and digital ulcers in systemic sclerosis.
• However, their use requires careful monitoring for potential side effects, particularly liver toxicity, fluid retention, and anemia.
• With ongoing research and medical advancements, endothelin receptor antagonists continue to play a significant role in improving the lives of patients affected by these challenging conditions.

References

• Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016 Jan 1;37(1):67-119. doi: 10.1093/eurheartj/ehv317. PMID: 26320113.
• Provencher S, Herve P, Jais X, Lebrec D, Humbert M, Simonneau G, Sitbon O. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology. 2006 Apr;130(4):120-6. doi: 10.1053/j.gastro.2005.12.012. PMID: 16618408.
• Provencher S, Jais X, Yaici A, Jaïs X, Lebrec D, Humbert M, Simonneau G, Sitbon O. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology. 2006 Apr;130(4):120-6. doi: 10.1053/j.gastro.2005.12.012. PMID: 16618408.